Browse Items (4 total)
- Tags: Remission Induction
Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study.
Tags: 1999, Adult, American journal of kidney diseases : the official journal of the National Kidney Foundation, Angiotensin-Converting Enzyme Inhibitors/*therapeutic use, Antihypertensive Agents/*therapeutic use, Bain R P, Blood Pressure/drug effects, Blumenthal S, Captopril/*therapeutic use, Cattran D, Chronic/etiology, Creatinine/blood, Department of Internal Medicine, Diabetes Mellitus, Diabetic Nephropathies/*drug therapy/physiopathology, Disease Progression, Female, Follow-Up Studies, Hebert L A, Humans, Kidney Failure, Levey A S, Lewis E J, Lewis J B, Male, Middle Aged, NEOMED College of Medicine, Nephrotic Syndrome/complications/*drug therapy/physiopathology, Prospective Studies, Proteinuria, Randomized Controlled Trials as Topic, Remission Induction, Rohde R D, Spitalewitz S, Type 1/*complications, Whittier F, Wilmer W A
Tags: *Skin Pigmentation, 2012, Adolescence, Adolescent, Adult, Aouthmany Mouhammad, Brodell Robert T, Child, Databases, Disease Progression, Disease Remission, Factual/*statistics & numerical data, Female, Follow-Up Studies, Halo – Pathology, Halo – Surgery, Halo/*pathology/*surgery, Human, Humans, Journal of the American Academy of Dermatology, Male, Middle Age, Middle Aged, Nevus, Preschool, Prospective Studies, Questionnaires, Remission, Remission Induction, Resource Databases, Retrospective Design, Retrospective Studies, Skin Pigmentation, Spontaneous, Surveys and Questionnaires, Weinstein Mara, Young Adult, Zirwas Matthew J
Complete remission in a patient with metastatic mixed adenocarcinoma/extrapulmonary small cell carcinoma of the prostate.
Tags: 2011, Adenocarcinoma/diagnosis/*secondary, Androgen Antagonists/therapeutic use, Bone Neoplasms/*drug therapy/*secondary, Brammer Jonathan Edward, Carcinoma, Cisplatin/therapeutic use, Combined Modality Therapy, Etoposide/therapeutic use, Humans, International journal of clinical oncology, Lulla Premal, Lung Neoplasms/diagnosis/*secondary, Lynch Garrett Rush, Male, Middle Aged, Prostatic Neoplasms/*drug therapy/metabolism/*pathology, Remission Induction, Small Cell/diagnosis/*secondary
Tags: 2015, 80 and over, Adenocarcinoma/drug therapy/mortality/pathology, adenoid cystic carcinoma, Adenoid Cystic/*drug therapy/mortality/pathology, Adult, Aged, Antineoplastic Agents/*therapeutic use, Blumenschein George R Jr, Carcinoma, Department of Internal Medicine, Disease-Free Survival, Dose-Response Relationship, Drug, Drug Administration Schedule, El-Naggar Adel K, Female, Gefitinib, Glisson Bonnie S, Gonzalez-Angulo Ana M, Head & neck, Humans, Jakob John A, Kies Merrill S, Kupferman Michael E, Lee J Jack, Liu Diane D, Local/*drug therapy/mortality/pathology, Male, Maximum Tolerated Dose, Middle Aged, NEOMED College of Medicine, Neoplasm Invasiveness/pathology, Neoplasm Recurrence, Neoplasm Staging, non-adenoid cystic carcinoma, Prognosis, Quinazolines/*therapeutic use, Remission Induction, response to therapy, salivary gland cancer, Salivary Gland Neoplasms/*drug therapy/mortality/pathology, Survival Analysis, Treatment Outcome